📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Recursion

1.1 - Company Overview

Recursion Logo

Recursion

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of a machine learning-driven drug discovery platform (Recursion OS), digital chemistry tools (MatchMaker), and an on-premise supercomputer (BioHive-1) to map complex biology and rapidly advance potential therapeutics; also collaborates with Bayer, Roche & Genentech, NVIDIA, Tempus, and Enamine.

Products and services

  • Recursion OS: An industrial-scale platform leveraging machine learning to map complex biology, integrate chemistry, automation, data science, and engineering, and rapidly identify and advance potential therapeutics
  • BioHive-1: An on-premise supercomputer accelerating development of AI foundation models for biology and chemistry, projected to be among the world's most powerful
  • MatchMaker: A computational digital chemistry product predicting ligand–protein interactions, identifying potential binding between any small molecule and any protein across the human proteome

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Recursion

Sagimet Biosciences Logo

Sagimet Biosciences

HQ: United States Website
  • Description: Provider of novel therapeutics targeting FASN, including Denifanstat, an oral, once-daily selective FASN inhibitor in development for MASH, acne, and certain cancers, and TVB-3567, a pipeline FASN inhibitor planned for U.S. clinical development for acne.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sagimet Biosciences company profile →
Acceleron Pharma Logo

Acceleron Pharma

HQ: United States Website
  • Description: Provider of novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases; engaged in developing, manufacturing, and commercializing these products, including the ACE-011 program, a novel bone-forming program.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Acceleron Pharma company profile →
Nurix Therapeutics Logo

Nurix Therapeutics

HQ: United States Website
  • Description: Provider of small molecule therapeutics and discovery via the DELigase platform leveraging E3 ligases and DNA-encoded libraries for targeted protein degradation (TPD) and elevation (TPE). Pipeline includes oral candidates NX-5948 (BTK degrader), NX-2127 (BTK/IKZF1/IKZF3 degrader), and NX-1607 (CBL-B inhibitor) for B-cell malignancies, solid tumors, and autoimmune diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Nurix Therapeutics company profile →
Endo Logo

Endo

HQ: Ireland Website
  • Description: Provider of branded and generic pharmaceuticals for patient care, offering affordable, high-quality generics and treatments for unmet pelvic health needs; supplies products tailored to Canadian and emerging markets, and engages in public policy advocacy to enhance patient access, alongside a UK tax strategy focused on compliance and responsible planning.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Endo company profile →
Antibe Therapeutics Logo

Antibe Therapeutics

HQ: Canada Website
  • Description: Provider of novel anti-inflammatory drugs that improve existing, proven therapies, targeting diseases characterized by inflammation, pain, and vascular dysfunction. Offers a proprietary hydrogen sulfide platform; pipeline includes Otenaproxesul for acute pain with demonstrated gastrointestinal safety and efficacy in chronic pain, ATB-352 for specialized pain, and a program for mild-to-moderate inflammatory bowel disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Antibe Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Recursion

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Recursion

2.2 - Growth funds investing in similar companies to Recursion

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Recursion

4.2 - Public trading comparable groups for Recursion

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Recursion

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Recursion

What does Recursion do?

Recursion is a provider of a machine learning-driven drug discovery platform (Recursion OS), digital chemistry tools (MatchMaker), and an on-premise supercomputer (BioHive-1) to map complex biology and rapidly advance potential therapeutics; also collaborates with Bayer, Roche & Genentech, NVIDIA, Tempus, and Enamine.

Who are Recursion's competitors?

Recursion's competitors and similar companies include Sagimet Biosciences, Acceleron Pharma, Nurix Therapeutics, Endo, and Antibe Therapeutics.

Where is Recursion headquartered?

Recursion is headquartered in United States.

How many employees does Recursion have?

Recursion has 1,000 employees 🔒.

When was Recursion founded?

Recursion was founded in 2010 🔒.

What sector and industry vertical is Recursion in?

Recursion is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Recursion

Who are the top strategic acquirers in Recursion's sector and industry

Top strategic M&A buyers and acquirers in Recursion's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Recursion?

Top strategic M&A buyers groups and sectors for Recursion include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Recursion's sector and industry vertical

Which are the top PE firms investing in Recursion's sector and industry vertical?

Top PE firms investing in Recursion's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Recursion's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Recursion's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Recursion's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Recursion include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Recursion's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Recursion?

The key public trading comparables and valuation benchmarks for Recursion include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Recursion for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Recursion with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Recursion's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Recursion with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Recursion's' sector and industry vertical?

Access recent funding rounds and capital raises in Recursion's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Recursion

Launch login modal Launch register modal